Abstract Background Patients with newly diagnosed non-metastatic prostate adenocarcinoma are typically classified as at low, intermediate, or high risk of disease progression using blood prostate-specific antigen concentration, tumour T category, and tumour pathological Gleason score. Classification is used to both predict clinical outcome and to inform initial management. However, significant heterogeneity is observed in outcome, particularly within the intermediate risk group, and there is an urgent need for additional markers to more accurately hone risk prediction. Recently developed web-based visualization and analysis tools have facilitated rapid interrogation of large transcriptome datasets, and querying broadly across multiple large...
Abstract Background: The early detection of prostate cancer has resulted in an increase in the numbe...
Abstract Background Prostate cancer is an extremely h...
One of the major challenges in the development of prostate cancer prognostic biomarkers is the cellu...
Abstract Background Patients with newly diagnosed non...
Background: One of the most common cancers that affect North American men and men worldwide is prost...
International audienceDetermining which treatment to provide to men with prostate cancer (PCa) is a ...
Background Prostate tumor heterogeneity and biopsy undersampling pose challenges to accurate, indivi...
Background Optimum management of clinically localised prostate cancer presents unique challenges bec...
SummaryBackgroundOptimum management of clinically localised prostate cancer presents unique challeng...
BackgroundProstate tumor heterogeneity and biopsy undersampling pose challenges to accurate, individ...
BACKGROUND: Optimum management of clinically localised prostate cancer presents unique challenges be...
Abstract. Background: High-throughput analyses yielded a large number of predictive biomarkers in p...
PURPOSE: Prostate-specific antigen screening has led to enormous overtreatment of prostate cancer...
<div><p>Purpose</p><p>Clinicopathologic features and biochemical recurrence are sensitive, but not s...
The recurrence of prostate cancer (PCa) is intrinsically linked to increased mortality. The goal of ...
Abstract Background: The early detection of prostate cancer has resulted in an increase in the numbe...
Abstract Background Prostate cancer is an extremely h...
One of the major challenges in the development of prostate cancer prognostic biomarkers is the cellu...
Abstract Background Patients with newly diagnosed non...
Background: One of the most common cancers that affect North American men and men worldwide is prost...
International audienceDetermining which treatment to provide to men with prostate cancer (PCa) is a ...
Background Prostate tumor heterogeneity and biopsy undersampling pose challenges to accurate, indivi...
Background Optimum management of clinically localised prostate cancer presents unique challenges bec...
SummaryBackgroundOptimum management of clinically localised prostate cancer presents unique challeng...
BackgroundProstate tumor heterogeneity and biopsy undersampling pose challenges to accurate, individ...
BACKGROUND: Optimum management of clinically localised prostate cancer presents unique challenges be...
Abstract. Background: High-throughput analyses yielded a large number of predictive biomarkers in p...
PURPOSE: Prostate-specific antigen screening has led to enormous overtreatment of prostate cancer...
<div><p>Purpose</p><p>Clinicopathologic features and biochemical recurrence are sensitive, but not s...
The recurrence of prostate cancer (PCa) is intrinsically linked to increased mortality. The goal of ...
Abstract Background: The early detection of prostate cancer has resulted in an increase in the numbe...
Abstract Background Prostate cancer is an extremely h...
One of the major challenges in the development of prostate cancer prognostic biomarkers is the cellu...